These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35954700)

  • 1. Women-Reported Barriers and Facilitators of Continued Engagement with Medications for Opioid Use Disorder.
    Fiddian-Green A; Gubrium A; Harrington C; Evans EA
    Int J Environ Res Public Health; 2022 Jul; 19(15):. PubMed ID: 35954700
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prescribing and Acceptance of Medications for Opioid Use Disorder in VA Primary Care: Veteran and Provider Perspectives.
    Bergman AA; Oberman RS; Taylor SL; Kranke B; Chang ET
    J Gen Intern Med; 2024 Jul; 39(9):1690-1697. PubMed ID: 38587730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating opioid use disorder in veterans with co-occurring substance use: a qualitative study with buprenorphine providers in primary care, mental health, and pain settings.
    Frost MC; Soyer EM; Achtmeyer CE; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
    Addict Sci Clin Pract; 2023 May; 18(1):26. PubMed ID: 37143162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "You have to take this medication, but then you get punished for taking it:" lack of agency, choice, and fear of medications to treat opioid use disorder across the perinatal period.
    Schiff DM; Work EC; Muftu S; Partridge S; MacMillan KDL; Gray JR; Hoeppner BB; Kelly JF; Greenfield SF; Jones HE; Wilens TE; Terplan M; Bernstein J
    J Subst Abuse Treat; 2022 Aug; 139():108765. PubMed ID: 35341614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Lived Experiences of Pregnant and Parenting Women in Recovery Toward Medication Treatment for Opioid Use Disorder.
    Titus-Glover D; Shaya FT; Welsh C; Roane L
    Subst Use Addctn J; 2024 Jul; 45(3):367-377. PubMed ID: 38254261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Barriers and facilitators to use of buprenorphine in state-licensed specialty substance use treatment programs: A survey of program leadership.
    Burke KN; Krawczyk N; Li Y; Byrne L; Desai IK; Bandara S; Feder KA
    J Subst Use Addict Treat; 2024 Jul; 162():209351. PubMed ID: 38499248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Massachusetts Justice Community Opioid Innovation Network (MassJCOIN).
    Evans EA; Stopka TJ; Pivovarova E; Murphy SM; Taxman FS; Ferguson WJ; Bernson D; Santelices C; McCollister KE; Hoskinson R; Lincoln T; Friedmann PD;
    J Subst Abuse Treat; 2021 Sep; 128():108275. PubMed ID: 33483222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying facilitators and barriers to the uptake of medication for opioid use disorder in Washington, DC: A community-engaged concept mapping approach.
    Gullahorn B; Kuo I; Robinson AM; Bailey J; Loken J; Taggart T
    PLoS One; 2024; 19(7):e0306931. PubMed ID: 39028730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration.
    Taylor EN; Timko C; Binswanger IA; Harris AHS; Stimmel M; Smelson D; Finlay AK
    Subst Abus; 2022; 43(1):556-563. PubMed ID: 34586978
    [No Abstract]   [Full Text] [Related]  

  • 11. Evaluation of medications used for opioid use disorder in emergency departments: A cross-sectional analysis of the 2020 National Hospital Ambulatory Medical Care Survey.
    Lee S; Sun L; Vakkalanka JP
    Am J Emerg Med; 2024 Aug; 82():52-56. PubMed ID: 38795424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
    Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
    JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "In their mind, they always felt less than": The role of peers in shifting stigma as a barrier to opioid use disorder treatment retention.
    Anvari MS; Kleinman MB; Massey EC; Bradley VD; Felton JW; Belcher AM; Magidson JF
    J Subst Abuse Treat; 2022 Jul; 138():108721. PubMed ID: 35067397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "And Then COVID Hits": A Qualitative Study of How Jails Adapted Services to Treat Opioid Use Disorder During COVID-19.
    Harrington C; Bailey A; Delorme E; Hano S; Evans EA
    Subst Use Misuse; 2023; 58(2):266-274. PubMed ID: 36510800
    [No Abstract]   [Full Text] [Related]  

  • 15. "Sick and tired of being sick and tired": Exploring initiation of medications for opioid use disorder among people experiencing homelessness.
    Swartz N; Adnan T; Peréa F; Baggett TP; Chatterjee A
    J Subst Abuse Treat; 2022 Jul; 138():108752. PubMed ID: 35277306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exemplar Hospital initiation trial to Enhance Treatment Engagement (EXHIT ENTRE): protocol for CTN-0098B a randomized implementation study to support hospitals in caring for patients with opioid use disorder.
    Bart G; Korthuis PT; Donohue JM; Hagedorn HJ; Gustafson DH; Bazzi AR; Enns E; McNeely J; Ghitza UE; Magane KM; Baukol P; Vena A; Harris J; Voronca D; Saitz R
    Addict Sci Clin Pract; 2024 Apr; 19(1):29. PubMed ID: 38600571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons.
    Treitler PC; Enich M; Reeves D; Crystal S
    Subst Abus; 2022; 43(1):964-971. PubMed ID: 35420973
    [No Abstract]   [Full Text] [Related]  

  • 19. Spatial and Nonspatial Factors Associated with Access to Medication for Opioid Use Disorder among Pregnant Women in Massachusetts.
    Joshi C; Ho Chui KK; Skeer MR; Stopka TJ
    Subst Use Misuse; 2022; 57(13):1904-1917. PubMed ID: 36219099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Access challenges to opioid use disorder treatment among individuals experiencing homelessness: Voices from the streets.
    Hsu M; Jung OS; Kwan LT; Jegede O; Martin B; Malhotra A; Suzuki J
    J Subst Use Addict Treat; 2024 Feb; 157():209216. PubMed ID: 37981243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.